Have you been diagnosed with Type 2 Diabetes? Are you currently taking metformin?
The REIMAGINE 2 trial by Novo Nordisk compares the efficacy of CagriSema in lowering the blood sugar and body weight of people with type 2 diabetes who are treated with metformin, with or without a semaglutide inhibitor. The efficacy of the study drug will be compared to semaglutide, cagrilintide, and a placebo.
Dr. John Agaiby, MD is the leading physician (principal investigator) for this trial at our clinic in Gurnee, IL. We are currently accepting new patients for this study.
For more information on this clinical trial, please call our Gurnee clinic at 847-599-2492 and ask to speak to our recruiters.
For more information about diabetes, click here to be redirected to the Center for Disease Control's (CDC) website, where lots of helpful information and resources are available.
Trial Protocol: NN9388-4896